Alexandros Polymeris, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 37 | 2023 | 9692 | 1.890 |
Why?
|
Brain Ischemia | 19 | 2023 | 3072 | 1.480 |
Why?
|
Atrial Fibrillation | 19 | 2024 | 5050 | 1.420 |
Why?
|
Anticoagulants | 23 | 2024 | 4732 | 1.060 |
Why?
|
Antifibrinolytic Agents | 2 | 2023 | 261 | 0.760 |
Why?
|
Tranexamic Acid | 1 | 2023 | 151 | 0.760 |
Why?
|
Hemostatics | 1 | 2023 | 234 | 0.730 |
Why?
|
Thrombolytic Therapy | 7 | 2022 | 2072 | 0.670 |
Why?
|
Thromboembolism | 2 | 2024 | 1003 | 0.590 |
Why?
|
Administration, Oral | 12 | 2024 | 3966 | 0.570 |
Why?
|
Ischemic Attack, Transient | 5 | 2022 | 895 | 0.560 |
Why?
|
Cerebral Hemorrhage | 10 | 2024 | 2617 | 0.550 |
Why?
|
Medication Adherence | 5 | 2024 | 2113 | 0.540 |
Why?
|
Intracranial Hemorrhages | 9 | 2023 | 836 | 0.530 |
Why?
|
Cerebrovascular Disorders | 2 | 2019 | 1484 | 0.470 |
Why?
|
Spastic Paraplegia, Hereditary | 1 | 2016 | 153 | 0.460 |
Why?
|
Vertebral Artery Dissection | 2 | 2024 | 51 | 0.410 |
Why?
|
Adenosine Triphosphatases | 1 | 2016 | 833 | 0.400 |
Why?
|
GTP-Binding Proteins | 1 | 2016 | 946 | 0.400 |
Why?
|
Secondary Prevention | 4 | 2024 | 1520 | 0.370 |
Why?
|
Vitamin K | 4 | 2021 | 311 | 0.370 |
Why?
|
Fibrinolytic Agents | 8 | 2024 | 2136 | 0.320 |
Why?
|
Aged, 80 and over | 23 | 2024 | 57552 | 0.300 |
Why?
|
Seizures | 1 | 2019 | 2880 | 0.280 |
Why?
|
Cerebral Amyloid Angiopathy | 2 | 2023 | 868 | 0.260 |
Why?
|
Recovery of Function | 3 | 2020 | 2924 | 0.250 |
Why?
|
Hematoma | 3 | 2024 | 768 | 0.230 |
Why?
|
Switzerland | 5 | 2022 | 309 | 0.220 |
Why?
|
Disability Evaluation | 2 | 2022 | 1804 | 0.200 |
Why?
|
Leukopenia | 1 | 2022 | 212 | 0.200 |
Why?
|
Siderosis | 1 | 2022 | 103 | 0.190 |
Why?
|
Carotid Artery, Internal, Dissection | 1 | 2021 | 42 | 0.190 |
Why?
|
Muscle Tonus | 1 | 2020 | 82 | 0.180 |
Why?
|
Aspirin | 2 | 2024 | 3287 | 0.180 |
Why?
|
Hepatolenticular Degeneration | 1 | 2020 | 72 | 0.180 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5465 | 0.170 |
Why?
|
Cerebral Arterial Diseases | 1 | 2019 | 81 | 0.170 |
Why?
|
Male | 31 | 2024 | 351098 | 0.170 |
Why?
|
Membrane Proteins | 1 | 2016 | 7785 | 0.170 |
Why?
|
Hyponatremia | 1 | 2022 | 276 | 0.170 |
Why?
|
Aged | 27 | 2024 | 164222 | 0.160 |
Why?
|
Hemorrhage | 5 | 2024 | 3522 | 0.160 |
Why?
|
Gait Disorders, Neurologic | 1 | 2020 | 233 | 0.150 |
Why?
|
Humans | 50 | 2024 | 746070 | 0.150 |
Why?
|
Female | 30 | 2024 | 382129 | 0.150 |
Why?
|
Prospective Studies | 14 | 2024 | 53219 | 0.140 |
Why?
|
Thrombocytopenia | 2 | 2022 | 1158 | 0.140 |
Why?
|
Cryoprotective Agents | 1 | 2017 | 120 | 0.140 |
Why?
|
Dimethyl Sulfoxide | 1 | 2017 | 252 | 0.140 |
Why?
|
Atherosclerosis | 2 | 2023 | 3416 | 0.140 |
Why?
|
Sodium | 1 | 2022 | 1604 | 0.140 |
Why?
|
Greece | 1 | 2016 | 346 | 0.130 |
Why?
|
Self Administration | 1 | 2016 | 382 | 0.130 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 17435 | 0.120 |
Why?
|
Treatment Outcome | 13 | 2024 | 63664 | 0.120 |
Why?
|
Recombinant Proteins | 1 | 2024 | 6505 | 0.120 |
Why?
|
Deglutition Disorders | 1 | 2019 | 610 | 0.110 |
Why?
|
Enteral Nutrition | 1 | 2019 | 769 | 0.110 |
Why?
|
Metformin | 1 | 2020 | 875 | 0.110 |
Why?
|
Cryopreservation | 1 | 2017 | 700 | 0.100 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2022 | 3118 | 0.100 |
Why?
|
Mutation | 1 | 2016 | 29620 | 0.100 |
Why?
|
Tissue Plasminogen Activator | 1 | 2017 | 1153 | 0.090 |
Why?
|
Drug Monitoring | 1 | 2017 | 948 | 0.090 |
Why?
|
Emergency Medical Services | 2 | 2019 | 1886 | 0.090 |
Why?
|
Liver Cirrhosis | 1 | 2020 | 1875 | 0.090 |
Why?
|
Risk Factors | 10 | 2023 | 72413 | 0.090 |
Why?
|
Registries | 4 | 2022 | 8170 | 0.090 |
Why?
|
Ambulatory Care | 1 | 2020 | 2717 | 0.090 |
Why?
|
Middle Aged | 17 | 2024 | 214419 | 0.090 |
Why?
|
Follow-Up Studies | 6 | 2022 | 38752 | 0.080 |
Why?
|
Cohort Studies | 8 | 2023 | 40505 | 0.080 |
Why?
|
Thrombectomy | 2 | 2023 | 676 | 0.080 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2019 | 2767 | 0.070 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 3027 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4119 | 0.070 |
Why?
|
Cross-Over Studies | 2 | 2023 | 2011 | 0.070 |
Why?
|
Prognosis | 4 | 2019 | 29072 | 0.070 |
Why?
|
Sex Characteristics | 1 | 2017 | 2558 | 0.070 |
Why?
|
Recurrence | 3 | 2021 | 8373 | 0.060 |
Why?
|
Factor Xa | 1 | 2024 | 165 | 0.050 |
Why?
|
Retrospective Studies | 8 | 2024 | 78293 | 0.050 |
Why?
|
Brain | 2 | 2019 | 26597 | 0.050 |
Why?
|
Time Factors | 5 | 2022 | 39589 | 0.050 |
Why?
|
Heart Valves | 1 | 2023 | 282 | 0.050 |
Why?
|
Phenprocoumon | 1 | 2021 | 20 | 0.050 |
Why?
|
Acenocoumarol | 1 | 2021 | 19 | 0.050 |
Why?
|
Pleura | 1 | 2023 | 243 | 0.050 |
Why?
|
Leukocytosis | 1 | 2022 | 243 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2017 | 5101 | 0.040 |
Why?
|
Disease Progression | 1 | 2016 | 13302 | 0.040 |
Why?
|
Germany | 1 | 2021 | 857 | 0.040 |
Why?
|
Denmark | 1 | 2021 | 745 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15539 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13196 | 0.040 |
Why?
|
Intubation, Gastrointestinal | 1 | 2019 | 160 | 0.040 |
Why?
|
Administration, Intravesical | 1 | 2018 | 90 | 0.040 |
Why?
|
Atrophy | 1 | 2022 | 1613 | 0.040 |
Why?
|
Thrombocytosis | 1 | 2018 | 82 | 0.040 |
Why?
|
Deglutition | 1 | 2019 | 201 | 0.040 |
Why?
|
Adult | 8 | 2024 | 214969 | 0.040 |
Why?
|
Chromogenic Compounds | 1 | 2017 | 31 | 0.040 |
Why?
|
Gastrostomy | 1 | 2019 | 316 | 0.030 |
Why?
|
Heparin | 1 | 2023 | 1631 | 0.030 |
Why?
|
Platelet Count | 1 | 2018 | 763 | 0.030 |
Why?
|
Risk Assessment | 3 | 2023 | 23454 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 841 | 0.030 |
Why?
|
Patient Admission | 1 | 2022 | 1358 | 0.030 |
Why?
|
Child, Preschool | 1 | 2016 | 41383 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4858 | 0.030 |
Why?
|
Warfarin | 1 | 2021 | 1482 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2020 | 2278 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25174 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 35781 | 0.020 |
Why?
|
Patient Discharge | 1 | 2022 | 3304 | 0.020 |
Why?
|
Acute Disease | 1 | 2019 | 7116 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9521 | 0.020 |
Why?
|
Hospitals | 1 | 2022 | 3852 | 0.020 |
Why?
|
Child | 1 | 2016 | 78469 | 0.020 |
Why?
|
Adolescent | 1 | 2016 | 86212 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9114 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5093 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 21676 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 3896 | 0.020 |
Why?
|
Prevalence | 1 | 2023 | 15306 | 0.020 |
Why?
|
Blood Pressure | 1 | 2021 | 8405 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 19804 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12632 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10127 | 0.020 |
Why?
|
Electrocardiography | 1 | 2016 | 6321 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18145 | 0.010 |
Why?
|
Incidence | 1 | 2019 | 20812 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8434 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20145 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 11941 | 0.010 |
Why?
|
United States | 1 | 2022 | 70368 | 0.010 |
Why?
|